Phase 4 · Exenatide

NCT01588418 trial results

Effect of Exenatide on Brain Glucose Uptake in Relations to Pancreatic, Adipose Tissue, and Hepatic Function

Participants
15
Status
completed
Completed
2015-07
Sponsor
The University of Texas Health Science Center at San Antonio

As posted on ClinicalTrials.gov (NCT01588418), updated at source Nov 24, 2017. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.

Primary outcome

What NCT01588418 measured first

Effect of Exenatide on Brain (Total Gray Matter) Glucose Metabolismμmol/(ml*min) · 120 minutes after exenatide or placebo injection · mean
MeasureEffect of Exenatide or Placebo on CMRglun=15
total gray matter CMRglu after Exenatide0.14(0.02)
total gray matter CMRglu after Placebo0.10(0.01)
The trial

How NCT01588418 was run

This research study will examine brain glucose metabolism after an overnight fast to determine the effect of exenatide on brain glucose metabolism and lipid metabolism.

  • Exenatide first, then Placebo: Exenatide 5mcg was injected subcutaneously 30 min before Oral Glucose Tolerance Test (OGTT)-PET study. The same subject was studied again a few weeks later with the same protocol with Placebo injection.
  • Placebo first, then Exenatide: Placebo was injected subcutaneously 30 min before OGTT-PET study. The same subject was studied again a few weeks later with the same protocol with injection of Exenatide 5mcg .
Who could join the trial

Inclusion Criteria: 1. Males age 18-65 years old 2. Patients must have Body Mass Index (BMI) between 25 and 40 kg/m2 3. 2-hour glucose concentration above 140mg/dl after 75g glucose load, ie, having impaired glucose tolerance or newly diagnosed type 2 diabetes. 4. Patients must have BMI of 25-40 kg/m2 5. Patients must have no known severe liver or kidney disease, cancer, neurologic, psychiatric or systemic disease, ability to understand the study. 6. Only patients whose body weight has been stable (±3-4 pounds) over the three months prior to study will be included. 7. Patients must have the following laboratory values: * Hematocrit ≥ 34 vol% * Serum creatinine\* ≤ 1.5 mg/dl in males and * Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT): ≤ 2.5 times upper limit of normal * Alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT): ≤ 2.5 times upper limit of normal * Alkaline phosphatase ≤ 2.5 times upper limit of normal * If serum creatinine is ≤ 1.5 mg/dl in males, the PI can grant an exception and not exclude the patient if the Glomerular filtration rate (GFR) is \>70 ml/min Exclusion Criteria: Patients are excluded from participation in the study if they meet any of the following criteria: 1. Patients with major chronic illness (cancer, liver, kidney, cardiovascular disease) 2. Patients with BMI over 40 and under 25 3. Patient with age below 18 yrs and over 65 yrs 4. Female subjects 5. Patients with type 1 diabetes 6. Patients treated for type 2 diabetes 7. Subjects with normal glucose tolerance (NGT)

Published papers

Papers from NCT01588418

Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.